The company intended to focus on developing novel immune engagers.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Oct 26, 2021 | Series A | $55M | 1 | ARCH Venture Partners | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
ARCH Venture Partners | Yes | Series A |